Giorgio Cannetti

Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience

Abstract Background Resistance to venetoclax (VEN)-based therapies is a therapeutic challenge in acute myeloid leukemia (AML). Objectives To evaluate the efficacy of clofarabine in combination with intermediate-dose cytarabine in patients with VEN-resistant AML. Methods Two real-...